Tissue Regenix Group plc (AIM:TRX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
7.25
0.00 (0.00%)
Inactive · Last trade price on Oct 22, 2025
Market Cap5.16M -86.6%
Revenue (ttm)20.26M +4.3%
Net Income-997.04K
EPS-0.01
Shares Out 71.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume102,223
Open7.25
Previous Close7.25
Day's Range7.00 - 7.50
52-Week Range4.77 - 66.00
Beta0.39
Analystsn/a
Price Targetn/a
Earnings DateDec 11, 2025

About Tissue Regenix Group

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a technology that natural bone filler solution for osteoinduct... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 92
Stock Exchange London Stock Exchange AIM
Ticker Symbol TRX
Full Company Profile

Financial Performance

In 2024, Tissue Regenix Group's revenue was $28.65 million, an increase of 8.85% compared to the previous year's $26.32 million. Losses were -$713,000, -58.38% less than in 2023.

Financial numbers in USD Financial Statements